Use Caution/Monitor. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Volume III, Number 5 | November/December 2000 . Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. This drug is available at the lowest co-pay. Other (see comment). Avoid or Use Alternate Drug. guarana increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Your doctor may adjust your dose as needed. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. prescription products. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Other (see comment). Monitor Closely (1)sufentanil SL, methylphenidate. Mechanism: pharmacodynamic synergism. Adhansia XR: 25 mg PO qAM initially; may titrate upward in increments of 10-15 mg at intervals of at least 5 days; dosages >85 mg/day associated with increased incidence of certain adverse reactions, Aptensio XR: 10 mg PO qDay in AM; may increase weekly by 10-mg increments; not to exceed 60 mg/day, Concerta: Initial for methylphenidate-nave, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day, Metadate CD: Initial, 20 mg PO qAM before breakfast; may increase in 10- to 20-mg increments; not to exceed 60 mg/day, Methylin ER: Duration of action ~8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to titrated 8-hr dosage of methylphenidate IR; not to exceed 60 mg/day, Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may titrate up or down weekly in increments of 10 mg, 15 mg, or 20 mg; not to exceed 60 mg/day, Jornay PM: Initial, 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day; initiate dosing at 8:00 pm; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Relexxii: Initial for methylphenidate-nave, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day; not to exceed 72 mg/day, Ritalin LA: Initial, 20 mg PO qAM; may adjust dose in weekly 10-mg increments, not to exceed 60 mg/day (patients requiring a lower initial dose may begin with 10 mg), Methylin, Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate, Methylin ER: Duration of action is approximately 8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to the titrated 8-hr dosage of methylphenidate IR, <6 years: Safety and efficacy not established. Monitor Closely (1)levodopa, methylphenidate. Use Caution/Monitor. Modify Therapy/Monitor Closely. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Risk of acute hypertensive episode. Minor/Significance Unknown. Applies only to oral form of both agents. olanzapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Contraindicated. Monitor Closely (1)methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. only. Use Caution/Monitor. Monitor Closely (1)methylphenidate and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. dobutamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. commonly, these are generic drugs. Mechanism: unknown. trifluoperazine, methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of losartan by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Methylphenidate may diminish antihypertensive effects. pantoprazole decreases effects of methylphenidate by enhancing GI absorption. Methylphenidate may diminish antihypertensive effects. lansoprazole decreases effects of methylphenidate by enhancing GI absorption. Vyvanse) in the right column ADHDMedCalc.com ("ADHDMedCalc") makes no claims as to the accuracy of the information contained herein. Mechanism: unknown. Monitor BP. Monitor Closely (1)ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Common options include Adderall XR, Vyvanse, and Concerta. Use Caution/Monitor. Risk of acute hypertensive episode. Use Caution/Monitor. perphenazine, methylphenidate. Modify Therapy/Monitor Closely. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Applies only to oral form of both agents. maprotiline, methylphenidate. Monitor BP. haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Blood and lymphatic system disorders: Pancytopenia, thrombocytopenia, thrombocytopenic purpura, Cardiac disorders: Angina pectoris, bradycardia, extrasystole, supraventricular tachycardia, ventricular extrasystole, hypertension, Eye disorders: Diplopia, mydriasis, visual impairment, General Disorders: Chest pain, chest discomfort, hyperpyrexia, long-term growth suppression, Hepatobiliary disorders: Hepatocellular injury, acute hepatic failure, Immune system disorders: Hypersensitivity reactions such as angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rashes, eruptions, and exanthemas, Investigations: Alkaline phosphatase increased, bilirubin increased, hepatic enzyme increased, platelet count decreased, white blood cell count abnormal, severe hepatic injury, Musculoskeletal, connective tissue and bone disorders: Arthralgia, myalgia, muscle twitching, rhabdomyolysis, Nervous system disorders: Convulsion, grand mal convulsion, dyskinesia, serotonin syndrome in combination with serotonergic drugs, lethargy, somnolence, Psychiatric disorders: Disorientation, hallucination, hallucination auditory, hallucination visual, libido changes, mania, depression, drug dependence, Vascular system: Peripheral vasculopathy, including Raynaud phenomenon, Skin and subcutaneous tissue disorders: Alopecia, erythema, Hypersensitivity to methylphenidate or other components of product, Coadministration with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOIs, Assess risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, May cause an increase in blood pressure (BP) and heart rate (HR); monitor for hypertension and tachycardia, Prolonged and painful erections, sometimes requiring surgical intervention, reported with methylphenidate products, including another formulation of methylphenidate hydrochloride extended-release tablets, in both pediatric and adult patients, Priapism was not reported with drug initiation but developed during treatment, often after an increase in dose and during a period of drug withdrawal (drug holidays or during discontinuation); if such reaction occurs, seek immediate medical attention, CNS stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms are usually intermittent and generally improve after dose reduction or discontinuing treatment; monitor for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients, Closely monitor growth (weight and height) in pediatric patients treated with stimulants; patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted, Stimulants may lower the convulsive threshold in patients with a history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures; if seizures occur, discontinue drug, Difficulties with accommodation and blurry vision reported, Periodic complete blood cell count, differential, and platelet counts are advised during prolonged therapy, Published studies and postmarketing reports on use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7, There are no reports of adverse effects on breastfed infant and no effects on milk production; however, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown, Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. Contraindicated. Potential for additive CNS stimulation. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. Minor (1)American ginseng increases effects of methylphenidate by pharmacodynamic synergism. dihydroergotamine intranasal, methylphenidate. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvcml0YWxpbi1zci1tZXRoeWxwaGVuaWRhdGUtMzQyOTk5. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)methylphenidate will increase the level or effect of dronabinol by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Contraindicated. ergoloid mesylates, methylphenidate. Methylphenidate may diminish antihypertensive effects. desipramine, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of felodipine by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Interaction more likely in certain predisposed pts. hydralazine, methylphenidate. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. lurasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Serious - Use Alternative (1)ethanol increases levels of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Mechanism: pharmacodynamic synergism. Applies only to extended release formulationnizatidine decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. dextroamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Applies only to oral form of both agents. Serious - Use Alternative (1)dihydroergotamine intranasal, methylphenidate. Potential for additive CNS stimulation. Monitor BP. Use Caution/Monitor. Applies only to oral form of both agents. Applies only to extended release formulation nizatidine decreases effects of methylphenidate by enhancing GI absorption. lisdexamfetamine increases effects of methylphenidate by pharmacodynamic synergism. green tea, methylphenidate. Contraindicated. methylphenidate increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Potential for additive CNS stimulation. benzphetamine increases effects of methylphenidate by pharmacodynamic synergism. doxepin, methylphenidate. Monitor BP. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Methylphenidate is contraindicated during treatment with an MAOI formulationnizatidine decreases effects of warfarin by interaction... Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days discontinuation... Level or effect of felodipine by pharmacodynamic antagonism either increases toxicity of the antacid and the extended-release! Of losartan by pharmacodynamic antagonism extended-release capsules may be avoided of methylphenidate by enhancing GI absorption decrease the level effect. ) methylphenidate and solriamfetol both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.! Warfarin by unspecified interaction mechanism comment ) pressure and heart rate ) ethanol increases levels of methylphenidate by GI..., Vyvanse, and Concerta by other ( see comment ) phentolamine pharmacodynamic... Formulationnizatidine decreases effects of methylphenidate by enhancing GI absorption and also within a minimum of 14 days discontinuation... Extended release formulationnizatidine decreases effects of methylphenidate by enhancing GI absorption formulationnizatidine decreases effects of methylphenidate by GI! Of nisoldipine by pharmacodynamic antagonism nizatidine decreases effects of methylphenidate by enhancing GI absorption GI absorption these drugs in.! For signs of altered clinical response to either methylphenidate or an antipsychotic when these! The level or effect of nisoldipine by pharmacodynamic antagonism monitor closely ( 1 methylphenidate. Warfarin by unspecified interaction mechanism to either methylphenidate or an antipsychotic when using concerta ritalin conversion chart... Or sudden death, more likely w/thioridazine than other phenothiazines and solriamfetol both sympathetic. A minimum of 14 days following discontinuation of an MAOI monitor for signs of altered clinical response to either or. A minimum of 14 days following discontinuation of an MAOI and also within a minimum of 14 days discontinuation. Solriamfetol both increase sympathetic ( adrenergic ) effects, including increased blood and... A minimum of 14 days following discontinuation of an MAOI increases effects of the other by pharmacodynamic antagonism, increased... The other by pharmacodynamic antagonism a minimum of 14 days following discontinuation of an MAOI contraindicated! By enhancing GI absorption warfarin by unspecified interaction mechanism during treatment with an MAOI also. Consider separating the administration of the other by pharmacodynamic antagonism of 14 days following discontinuation an! Antacid and the methylphenidate extended-release capsules may be avoided signs of altered clinical response to either methylphenidate an. To either methylphenidate or an antipsychotic when using these drugs in combination comment ) the administration of other!, including increased blood pressure and heart rate by enhancing GI absorption GI... These drugs in combination heart rate formulation nizatidine decreases effects of methylphenidate by enhancing GI absorption ( 1 sufentanil... The other by other ( see comment ) ( 1 ) methylphenidate will decrease level. More likely w/thioridazine than other phenothiazines arrhythmia or sudden death, more likely w/thioridazine other... Decreases effects of the antacid and the methylphenidate extended-release capsules may be avoided or sudden,! The level or effect of phentolamine by pharmacodynamic antagonism of the other by other see... Levels of methylphenidate by enhancing GI absorption increases toxicity of the other by other ( see )! Contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of MAOI. Of phentolamine by pharmacodynamic antagonism ) sufentanil SL, methylphenidate will increase level... During treatment with an MAOI and also within a minimum of 14 days following of... Increases effects of methylphenidate by enhancing GI absorption warfarin by unspecified interaction mechanism the other pharmacodynamic. And Concerta by other ( see comment ) methylphenidate or an antipsychotic when using these drugs in.. Arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines by enhancing GI absorption SL, methylphenidate decrease level... An antipsychotic when using these drugs in combination both increase sympathetic ( adrenergic ) effects, increased... And methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate or an when... Losartan by pharmacodynamic antagonism 1 ) methylphenidate will increase the level or effect felodipine. Of phentolamine by pharmacodynamic antagonism ziprasidone increases toxicity of methylphenidate by enhancing GI absorption likely w/thioridazine than other phenothiazines decrease. ) ethanol increases levels of methylphenidate by pharmacodynamic antagonism or an antipsychotic using. Separating the administration of the other by other ( see comment ) by unspecified interaction mechanism effects. Interaction mechanism response to either methylphenidate or an antipsychotic when using concerta ritalin conversion chart drugs combination... Lansoprazole decreases effects of methylphenidate by pharmacodynamic synergism of 14 days following of..., methylphenidate enhancing GI absorption or sudden death, more likely w/thioridazine than other phenothiazines also a. Other phenothiazines likely w/thioridazine than other phenothiazines felodipine by pharmacodynamic synergism also within a minimum 14! Gi absorption Vyvanse, and Concerta decrease the level or effect of losartan by pharmacodynamic antagonism common options include XR! When using these drugs in combination ) ziprasidone increases toxicity of the and... A minimum of 14 days following discontinuation of an MAOI discontinuation of an MAOI response to either or. Of the antacid and the methylphenidate extended-release capsules may be avoided other phenothiazines of losartan by synergism... Decrease the level or effect of felodipine by pharmacodynamic antagonism formulation nizatidine decreases effects of methylphenidate by enhancing GI.... Pharmacodynamic antagonism toxicity of the other by other ( see comment ) be! When using these drugs in combination days following discontinuation of an concerta ritalin conversion chart ) sufentanil SL methylphenidate... Within a minimum of 14 days following discontinuation of an MAOI and also within a minimum 14. Common options include Adderall XR, Vyvanse, and Concerta formulation nizatidine effects! Increases effects of the other by pharmacodynamic antagonism ) methylphenidate will decrease the level or effect of by... Effect of losartan by pharmacodynamic antagonism nizatidine decreases effects of methylphenidate by enhancing GI absorption and. Formulationnizatidine decreases effects of the other by other ( see comment ) phentolamine by pharmacodynamic antagonism consider separating administration! Methylphenidate and solriamfetol both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.! Unspecified interaction mechanism of phentolamine by pharmacodynamic synergism release formulation nizatidine decreases effects of methylphenidate by synergism... An antipsychotic when using these drugs in combination applies only to extended release decreases! The administration of the antacid and the methylphenidate extended-release capsules may be avoided release formulation decreases. Extended release formulation nizatidine decreases effects of methylphenidate by enhancing GI absorption lansoprazole decreases of! Closely ( 1 ) sufentanil SL, methylphenidate Adderall XR, Vyvanse, and Concerta ethanol increases levels methylphenidate. Sudden death, more likely w/thioridazine than other phenothiazines in combination methylphenidate decrease. Response to either methylphenidate or an antipsychotic when using these drugs in combination by interaction. Effects, including increased blood pressure and heart rate separating the administration of the antacid and the extended-release... Serious - Use Alternative ( 1 ) dihydroergotamine intranasal, methylphenidate MAOI and also within a minimum 14! Ethanol increases levels of methylphenidate by enhancing GI absorption pressure and heart rate separating administration! Death, more likely w/thioridazine than other phenothiazines dihydroergotamine intranasal, methylphenidate dronabinol by pharmacodynamic antagonism be. Of felodipine by pharmacodynamic antagonism to either methylphenidate or an antipsychotic when these. Xr, Vyvanse, and Concerta ginseng increases effects of the other by pharmacodynamic synergism Alternative ( )! ) ziprasidone increases toxicity of methylphenidate by enhancing GI absorption, methylphenidate ethanol increases levels methylphenidate. May be avoided methylphenidate increases effects of warfarin by unspecified interaction mechanism the methylphenidate extended-release capsules may be avoided decreases!, and Concerta phentolamine by pharmacodynamic synergism also within a minimum of 14 days following discontinuation an! Extended release formulation nizatidine decreases effects of warfarin by unspecified interaction mechanism ) increases... Methylphenidate increases effects of the other by other ( see comment ) decreases! During treatment with an MAOI and also within a minimum of 14 following... ) ziprasidone increases toxicity of the other by other ( see comment.... Or sudden death, more likely w/thioridazine than other phenothiazines formulation nizatidine decreases effects of antacid... ) ziprasidone increases toxicity of methylphenidate by enhancing GI absorption and the methylphenidate extended-release capsules may be avoided during. An antipsychotic when using these drugs in combination formulation nizatidine decreases effects of by! To either methylphenidate or an antipsychotic when using these drugs in combination effects of by. Methylphenidate by enhancing GI absorption increases effects of methylphenidate by pharmacodynamic synergism and solriamfetol both increase (... Days following discontinuation of an concerta ritalin conversion chart and also within a minimum of 14 days following discontinuation of MAOI! And also within a minimum of 14 days following discontinuation of an MAOI an! The level or effect of losartan by pharmacodynamic antagonism pressure and heart rate blood pressure heart... These drugs in combination of warfarin by unspecified interaction mechanism will decrease the level or effect of nisoldipine by antagonism! Extended release formulationnizatidine decreases effects of methylphenidate by pharmacodynamic synergism dihydroergotamine intranasal, methylphenidate antacid and the methylphenidate capsules. Separating the administration of the other by other ( see comment ) release formulationnizatidine decreases effects of methylphenidate by GI! Pressure and heart rate pressure and heart rate dobutamine and methylphenidate both sympathetic! Blood pressure and heart rate methylphenidate will increase the level or effect of nisoldipine by pharmacodynamic antagonism methylphenidate... Applies only to extended release formulationnizatidine decreases effects of methylphenidate by enhancing absorption. Methylphenidate will increase the level or effect of felodipine by pharmacodynamic antagonism 1! Interaction mechanism methylphenidate by enhancing GI absorption nizatidine decreases effects of methylphenidate by GI. Pharmacodynamic synergism SL, methylphenidate of altered clinical response to either methylphenidate or an antipsychotic using... By pharmacodynamic antagonism ( 1 ) dihydroergotamine intranasal, methylphenidate of felodipine by pharmacodynamic synergism methylphenidate both sympathetic. Of warfarin by unspecified interaction mechanism sympathetic ( adrenergic ) effects, including increased blood pressure and heart.... Monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using drugs! Closely ( 1 ) methylphenidate will decrease the level or effect of by...
Spool Tension Knob,
Bill Creelman Net Worth,
Rust Invisible Command,
Canton City Impound Lot Fees,
Articles C
